From the bench to the bedside: ways to improve rituximab efficacy
Guillaume Cartron(Hôpital Saint Eloi), Philippe Solal‐Céligny(Institut de Cancérologie de l'Ouest)
Cited by 518
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
|Blood|2019|136
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
|Nature Medicine|2024|127
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
|The Lancet Haematology|2018|116